• •CurifyLabs closed a €12 million Series A funding round led by undisclosed investors to fuel U.S. expansion.
• •The startup focuses on automating the compounding process for personalized medication, aiming to replace manual pharmacy methods.
• •The firm has not yet detailed how the funding will be split between market entry costs and R&D requirements for regulatory approvals in the U.S. market.

Finnish health-tech firm CurifyLabs raised €12 million in Series A funding to expand its automated personalized medicine platform into the United States. Unlike traditional manual compounding, which is labor-intensive and prone to human error, the company’s hardware-software solution aims to standardize the production of patient-specific doses. Scaling into the U.S. market presents a major hurdle, however, due to the complex state-by-state regulatory landscape for pharmaceutical compounding. Whether the company can navigate these legal requirements will determine if its automated model can gain traction against established hospital pharmacy workflows.